Beta Bugs appoints Dr Alan Tinch as CEO to lead genetics strategy
The company aims to strengthen its position in the global insect protein market through superior BSF genetics
UK – Beta Bugs Ltd, a UK-based developer of premium Black Soldier Fly (BSF) genetics, has named Dr Alan Tinch as Chief Executive Officer, effective February 2026.
Dr Tinch’s appointment follows the company’s 2025 decision to concentrate solely on BSF genetics, moving away from pilot-scale production. The shift aims to leverage Beta Bugs’ strength in developing high-quality genetic strains amid a growing global demand for insect protein.
Dr Tinch brings more than 35 years of experience in farm animal and aquaculture genetics and breeding. He has expertise in developing genetic technologies and in commercialising products across international markets.
Since late 2025, he has worked with Beta Bugs and the Science Advisory Board to audit the company’s genetics programme thoroughly.
“The global BSF industry is scaling rapidly, and demand for genetics that deliver reliable and superior performance is accelerating,” Dr Tinch said. “Beta Bugs has established strong foundational work in BSF genetics, and I’m excited to lead the team as we demonstrate significant improvements in valuable traits and build sustainable trading partnerships with BSF producers worldwide.”
Focusing on high-performance genetics
Under the new strategy, Beta Bugs is dedicating resources to developing and validating high-performance BSF strains through rigorous internal and external testing. Independent trials are ongoing to confirm the genetic potential and resilience of the company’s products.
Chris Richards, Chair of Beta Bugs Ltd, said, “Alan’s scientific rigour, commercial acumen, and sector expertise position him perfectly to lead Beta Bugs through this next phase. The Board has complete confidence in his ability to establish Beta Bugs as a leading genetics provider to the global BSF industry.”
The appointment aligns with Beta Bugs’ recent investment in new laboratory facilities in the UK, estimated at £1 million (US$1.2 million), aimed at expanding the company’s capacity for genetic testing and strain development. These facilities will support advanced breeding programs and partnerships with international BSF producers.
Beta Bugs also recently launched a collaborative project with a major European feed company to improve BSF performance for sustainable animal protein production. The project is expected to generate €3.3 million (US$3.6 million) in revenue over the next three years, providing a strong commercial foundation for the company’s genetics-focused strategy.
With Dr Tinch at the helm, Beta Bugs aims to strengthen its position as a global leader in BSF genetics, ensuring producers worldwide have access to robust and high-performing insect strains that meet increasing market demand.
Be the first to leave a comment